Overall survival of patients with advanced colorectal cancer correlates with availability of fluorouracil, irinotecan, and oxaliplatin regardless of whether doublet or single-agent therapy is used first line

被引：217
作者：
Grothey, A [1 ]
Sargent, D [1 ]
机构：
[1] Mayo Clin, Coll Med, Rochester, MN 55905 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 36期
关键词：
D O I：
10.1200/JCO.2005.04.4792
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9441 / 9442
页数：2
相关论文
共 13 条
[1]  
[Anonymous], 2002, P ASCO
[2]   Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].
de Gramont, A ;
Figer, A ;
Seymour, M ;
Homerin, M ;
Hmissi, A ;
Cassidy, J ;
Boni, C ;
Cortes-Funes, H ;
Cervantes, A ;
Freyer, G ;
Papamichael, D ;
Le Bail, N ;
Louvet, C ;
Hendler, D ;
de Braud, F ;
Wilson, C ;
Morvan, F ;
Bonetti, A .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947
[3]  
DEGRAMONT A, 2004, J CLIN ONCOL, V22, pS14
[4]   Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial [J].
Douillard, JY ;
Cunningham, D ;
Roth, AD ;
Navarro, M ;
James, RD ;
Karasek, P ;
Jandik, P ;
Iveson, T ;
Carmichael, J ;
Alakl, M ;
Gruia, G ;
Awad, L ;
Rougier, P .
LANCET, 2000, 355 (9209) :1041-1047
[5]   A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].
Goldberg, RM ;
Sargent, DJ ;
Morton, RF ;
Fuchs, CS ;
Ramanathan, RK ;
Williamson, SK ;
Findlay, BP ;
Pitot, HC ;
Alberts, SR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30
[6]   Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment [J].
Grothey, A ;
Sargent, D ;
Goldberg, RM ;
Schmoll, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1209-1214
[7]   Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].
Hurwitz, H ;
Fehrenbacher, L ;
Novotny, W ;
Cartwright, T ;
Hainsworth, J ;
Heim, W ;
Berlin, J ;
Baron, A ;
Griffing, S ;
Holmgren, E ;
Ferrara, N ;
Fyfe, G ;
Rogers, B ;
Ross, R ;
Kabbinavar, F .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342
[8]   Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer:: European Organisation for Research and Treatment of Cancer Gastrointestinal Group study 40986 [J].
Köhne, CH ;
van Cutsem, E ;
Wils, J ;
Bokemeyer, C ;
El-Serafi, M ;
Lutz, MP ;
Lorenz, M ;
Reichardt, P ;
Rückle-Lanz, H ;
Frickhofen, N ;
Fuchs, R ;
Mergenthaler, HG ;
Langenbuch, T ;
Vanhoefer, U ;
Rougier, P ;
Voigtmann, R ;
Müller, L ;
Genicot, B ;
Anak, Ö ;
Nordlinger, B .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :4856-4865
[9]  
Oratz R, 2005, J CLIN ONCOL, V23, p49S
[10]  
PITOT HC, 2005, J CLIN ONCOL, V23, pS16
12